Kempen is pleased to announce that it acted as placing agent for Investinor in the secondary sell-down of c. 4 million Calliditas Therapeutics shares.
Investinor is an evergreen investment company funded by the Norwegian government, investing on the same terms and conditions as private investors, with a clear exit strategy for all investments. Investinor manages NOK 8 billion and focuses on early-stage private companies.
Calliditas Therapeutics AB is a specialty pharma focused on treatments for orphan indications, with an initial focus on renal and hepatic diseases with high unmet medical needs. The lead asset, Nefecon, is an oral formulation of budesonide, developed for the treatment of the autoimmune renal disease IgA nephropathy. Last weekend, Calliditas announced positive topline data from the Phase III trial with Nefecon.
Calliditas was listed on Nasdaq Stockholm in 2018 and the Nasdaq Global Select Market in 2020. On 9 November, Calliditas stock closed at SEK 146.8 on Nasdaq Stockholm giving it a market cap of SEK 7.4 billion (c. EUR 720 million).